Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury

Autor: Xin Xu, Amit Gaggar, Shi Wei, Hongwei Qin, Jiping Zhao, Sara A. Gibson, Chenglong Li, Hao Yu, Etty N. Benveniste, Yudong Liu, Pui-Kai Li, Zhaoqi Yan
Rok vydání: 2016
Předmět:
Lipopolysaccharides
STAT3 Transcription Factor
0301 basic medicine
Pulmonary and Respiratory Medicine
ARDS
Physiology
Acute Lung Injury
Anthraquinones
Cell Separation
Acute respiratory distress
Lung injury
03 medical and health sciences
0302 clinical medicine
Physiology (medical)
Animals
Humans
Medicine
Myeloid Cells
STAT3
Inflammation
Respiratory Distress Syndrome
Sulfonamides
Integrases
biology
business.industry
Macrophages
High mortality
JAK-STAT signaling pathway
Pneumonia
Cell Biology
respiratory system
medicine.disease
respiratory tract diseases
Mice
Inbred C57BL

Disease Models
Animal

030104 developmental biology
Gene Expression Regulation
Suppressor of Cytokine Signaling 3 Protein
030220 oncology & carcinogenesis
Immunology
Call for Papers
Leukocytes
Mononuclear

biology.protein
Chemokines
Inflammation Mediators
business
Bronchoalveolar Lavage Fluid
Gene Deletion
Zdroj: American Journal of Physiology-Lung Cellular and Molecular Physiology. 311:L868-L880
ISSN: 1522-1504
1040-0605
Popis: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are diseases with high mortality. Macrophages and neutrophils are responsible for inflammatory responses in ALI and ARDS, which are characterized by excessive production of proinflammatory mediators in bronchoalveolar lavage fluid (BALF) and plasma. Aberrant activation of the JAK/STAT pathway is critical for persistent inflammation in many conditions such as infection and autoimmunity. Given the importance of the STAT3 transcription factor in activating macrophages and neutrophils and augmenting inflammation, we investigated the therapeutic potential of inhibiting STAT3 activity using the small-molecule STAT3 inhibitor, LLL12. Our results demonstrate that LPS induces STAT3 activation in macrophages in vitro and in CD45+CD11b+ cells from BALF in the LPS-induced ALI model in vivo. LLL12 treatment inhibits LPS-induced lung inflammation in the ALI model, which is accompanied by suppression of LPS-induced STAT3 activation and an inhibition of macrophage and inflammatory cell infiltration in lung and BALF. LLL12 treatment also suppresses expression of proinflammatory genes including IL-1β, IL-6, TNF-α, iNOS, CCL2, and MHC class II in macrophages and inflammatory cells from BALF and serum as determined by ELISA. Furthermore, hyperactivation of STAT3 in LysMCre-SOCS3fl/fl mice accelerates the severity of inflammation in the ALI model. Both pre- and post-LPS treatment with LLL12 decrease LPS-induced inflammatory responses in mice with ALI. Importantly, LLL12 treatment attenuates STAT3 phosphorylation in human peripheral blood mononuclear cells induced by plasma from patients with ARDS, which suggests the feasibility of targeting the STAT3 pathway therapeutically for patients with ALI and ARDS.
Databáze: OpenAIRE